1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2. MARKET SNAPSHOT, 2022-2030 MILLION USD
2.1. MARKET SNAPSHOT
3. PORTER’S FIVE FORCE MODEL ANALYSIS
4. MARKET DYNAMICS
4.1. GROWTH DRIVERS
4.1.1 DRIVER 1
4.1.2 DRIVER 2
4.1.3 DRIVER 3
4.1.4 DRIVER 4
4.2. CHALLENGES
4.2.1 CHALLENGE 1
4.2.2 CHALLENGE 2
4.3. OPPORTUNITIES
4.3.1 OPPORTUNITY 1
4.3.2 OPPORTUNITY 2
5. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
5.1. OVERVIEW
5.2. IMMUNOHISTOCHEMISTRY
5.2.1 IMMUNOHISTOCHEMISTRY MARKET, BY REGION
5.2.1.1 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY
5.2.1.2 EUROPE IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY
5.2.1.3 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY
5.2.1.4 REST OF WORLD IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY
5.3. POLYMERASE CHAIN REACTION (PCR)
5.3.1 POLYMERASE CHAIN REACTION (PCR) MARKET, BY REGION
5.3.1.1 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY
5.3.1.2 EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY
5.3.1.3 ASIA-PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY
5.3.1.4 REST OF WORLD POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY
5.4. NEXT GENERATION SEQUENCING (NGS)
5.4.1 NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION
5.4.1.1 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY
5.4.1.2 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY
5.4.1.3 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY
5.4.1.4 REST OF WORLD NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY
5.5. IN SITU HYBRIDIZATION
5.5.1 IN SITU HYBRIDIZATION MARKET, BY REGION
5.5.1.1 NORTH AMERICA IN SITU HYBRIDIZATION MARKET, BY COUNTRY
5.5.1.2 EUROPE IN SITU HYBRIDIZATION MARKET, BY COUNTRY
5.5.1.3 ASIA-PACIFIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY
5.5.1.4 REST OF WORLD IN SITU HYBRIDIZATION MARKET, BY COUNTRY
5.6. OTHER TECHNOLOGY
5.6.1 OTHER TECHNOLOGY MARKET, BY REGION
5.6.1.1 NORTH AMERICA OTHER TECHNOLOGY MARKET, BY COUNTRY
5.6.1.2 EUROPE OTHER TECHNOLOGY MARKET, BY COUNTRY
5.6.1.3 ASIA-PACIFIC OTHER TECHNOLOGY MARKET, BY COUNTRY
5.6.1.4 REST OF WORLD OTHER TECHNOLOGY MARKET, BY COUNTRY
6. GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION
6.1. OVERVIEW
6.2. ONCOLOGY
6.2.1 GLOBAL ONCOLOGY MARKET, BY INDICATION
6.2.1.1 LUNG CANCER MARKET, BY REGION
6.2.1.1.1 NORTH AMERICA LUNG CANCER MARKET, BY COUNTRY
6.2.1.1.2 EUROPE LUNG CANCER MARKET, BY COUNTRY
6.2.1.1.3 ASIA-PACIFIC LUNG CANCER MARKET, BY COUNTRY
6.2.1.1.4 REST OF WORLD LUNG CANCER MARKET, BY COUNTRY
6.2.1.2 COLORECTAL CANCER MARKET, BY REGION
6.2.1.2.1 NORTH AMERICA COLORECTAL CANCER MARKET, BY COUNTRY
6.2.1.2.2 EUROPE COLORECTAL CANCER MARKET, BY COUNTRY
6.2.1.2.3 ASIA-PACIFIC COLORECTAL CANCER MARKET, BY COUNTRY
6.2.1.2.4 REST OF WORLD COLORECTAL CANCER MARKET, BY COUNTRY
6.2.1.3 BREAST CANCER MARKET, BY REGION
6.2.1.3.1 NORTH AMERICA BREAST CANCER MARKET, BY COUNTRY
6.2.1.3.2 EUROPE BREAST CANCER MARKET, BY COUNTRY
6.2.1.3.3 ASIA-PACIFIC BREAST CANCER MARKET, BY COUNTRY
6.2.1.3.4 REST OF WORLD BREAST CANCER MARKET, BY COUNTRY
6.2.1.4 BLOOD CANCER MARKET, BY REGION
6.2.1.4.1 NORTH AMERICA BLOOD CANCER MARKET, BY COUNTRY
6.2.1.4.2 EUROPE BLOOD CANCER MARKET, BY COUNTRY
6.2.1.4.3 ASIA-PACIFIC BLOOD CANCER MARKET, BY COUNTRY
6.2.1.4.4 REST OF WORLD BLOOD CANCER MARKET, BY COUNTRY
6.2.1.5 OTHERS MARKET, BY REGION
6.2.1.5.1 NORTH AMERICA OTHERS MARKET, BY COUNTRY
6.2.1.5.2 EUROPE OTHERS MARKET, BY COUNTRY
6.2.1.5.3 ASIA-PACIFIC OTHERS MARKET, BY COUNTRY
6.2.1.5.4 REST OF WORLD OTHERS MARKET, BY COUNTRY
6.2.2 ONCOLOGY MARKET, BY REGION
6.2.2.1 NORTH AMERICA ONCOLOGY MARKET, BY COUNTRY
6.2.2.2 EUROPE ONCOLOGY MARKET, BY COUNTRY
6.2.2.3 ASIA-PACIFIC ONCOLOGY MARKET, BY COUNTRY
6.2.2.4 REST OF WORLD ONCOLOGY MARKET, BY COUNTRY
6.3. NEUROLOGY
6.3.1 NEUROLOGY MARKET, BY REGION
6.3.1.1 NORTH AMERICA NEUROLOGY MARKET, BY COUNTRY
6.3.1.2 EUROPE NEUROLOGY MARKET, BY COUNTRY
6.3.1.3 ASIA-PACIFIC NEUROLOGY MARKET, BY COUNTRY
6.3.1.4 REST OF WORLD NEUROLOGY MARKET, BY COUNTRY
6.4. OTHER INDICATION
6.4.1 OTHER INDICATION MARKET, BY REGION
6.4.1.1 NORTH AMERICA OTHER INDICATION MARKET, BY COUNTRY
6.4.1.2 EUROPE OTHER INDICATION MARKET, BY COUNTRY
6.4.1.3 ASIA-PACIFIC OTHER INDICATION MARKET, BY COUNTRY
6.4.1.4 REST OF WORLD OTHER INDICATION MARKET, BY COUNTRY
7. GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.2.2 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.2.2.1 NORTH AMERICA ONCOLOGY MARKET, BY INDICATION
7.2.3 NORTH AMERICA COMPANION DIAGNOSTICS, MARKET BY COUNTRY
7.2.3.1 U.S.
7.2.3.1.1 U.S. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.2.3.1.2 U.S. COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.2.3.1.2.1. U.S. ONCOLOGY MARKET, BY INDICATION
7.2.3.2 CANADA
7.2.3.2.1 CANADA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.2.3.2.2 CANADA COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.2.3.2.2.1. CANADA ONCOLOGY MARKET, BY INDICATION
7.2.3.3 MEXICO
7.2.3.3.1 MEXICO COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.2.3.3.2 MEXICO COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.2.3.3.2.1. MEXICO ONCOLOGY MARKET, BY INDICATION
7.3. EUROPE
7.3.1 EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.3.2 EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.3.2.1 EUROPE ONCOLOGY MARKET, BY INDICATION
7.3.3 EUROPE COMPANION DIAGNOSTICS, MARKET BY COUNTRY
7.3.3.1 GERMANY
7.3.3.1.1 GERMANY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.3.3.1.2 GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.3.3.1.2.1. GERMANY ONCOLOGY MARKET, BY INDICATION
7.3.3.2 UK
7.3.3.2.1 UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.3.3.2.2 UK COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.3.3.2.2.1. UK ONCOLOGY MARKET, BY INDICATION
7.3.3.3 FRANCE
7.3.3.3.1 FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.3.3.3.2 FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.3.3.3.2.1. FRANCE ONCOLOGY MARKET, BY INDICATION
7.3.3.4 REST OF EUROPE
7.3.3.4.1 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.3.3.4.2 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.3.3.4.2.1. REST OF EUROPE ONCOLOGY MARKET, BY INDICATION
7.4. ASIA-PACIFIC
7.4.1 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.4.2 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.4.2.1 ASIA-PACIFIC ONCOLOGY MARKET, BY INDICATION
7.4.3 ASIA-PACIFIC COMPANION DIAGNOSTICS, MARKET BY COUNTRY
7.4.3.1 AUSTRALIA
7.4.3.1.1 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.4.3.1.2 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.4.3.1.2.1. AUSTRALIA ONCOLOGY MARKET, BY INDICATION
7.4.3.2 JAPAN
7.4.3.2.1 JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.4.3.2.2 JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.4.3.2.2.1. JAPAN ONCOLOGY MARKET, BY INDICATION
7.4.3.3 CHINA
7.4.3.3.1 CHINA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.4.3.3.2 CHINA COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.4.3.3.2.1. CHINA ONCOLOGY MARKET, BY INDICATION
7.4.3.4 REST OF ASIA-PACIFIC
7.4.3.4.1 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.4.3.4.2 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.4.3.4.2.1. REST OF ASIA-PACIFIC ONCOLOGY MARKET, BY INDICATION
7.5. REST OF WORLD
7.5.1 REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.5.2 REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.5.2.1 REST OF WORLD ONCOLOGY MARKET, BY INDICATION
7.5.3 REST OF WORLD COMPANION DIAGNOSTICS, MARKET BY COUNTRY
7.5.3.1 BRAZIL
7.5.3.1.1 BRAZIL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.5.3.1.2 BRAZIL COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.5.3.1.2.1. BRAZIL ONCOLOGY MARKET, BY INDICATION
7.5.3.2 SOUTH AFRICA
7.5.3.2.1 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.5.3.2.2 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.5.3.2.2.1. SOUTH AFRICA ONCOLOGY MARKET, BY INDICATION
7.5.3.3 REMAINING COUNTRIES
7.5.3.3.1 REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.5.3.3.2 REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET, BY INDICATION
7.5.3.3.2.1. REMAINING COUNTRIES ONCOLOGY MARKET, BY INDICATION
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES MOLECULAR, INC.
8.1.1 COMPANY OVERVIEW
8.1.2 COMPANY SNAPSHOT
8.1.3 OPERATING BUSINESS SEGMENTS
8.1.4 PRODUCT PORTFOLIO
8.1.5 BUSINESS PERFORMANCE
8.1.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.2. AGILENT
8.2.1 COMPANY OVERVIEW
8.2.2 COMPANY SNAPSHOT
8.2.3 OPERATING BUSINESS SEGMENTS
8.2.4 PRODUCT PORTFOLIO
8.2.5 BUSINESS PERFORMANCE
8.2.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.3. ARUP LABORATORIES, INC.
8.3.1 COMPANY OVERVIEW
8.3.2 COMPANY SNAPSHOT
8.3.3 OPERATING BUSINESS SEGMENTS
8.3.4 PRODUCT PORTFOLIO
8.3.5 BUSINESS PERFORMANCE
8.3.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.4. BIOMERIEUX
8.4.1 COMPANY OVERVIEW
8.4.2 COMPANY SNAPSHOT
8.4.3 OPERATING BUSINESS SEGMENTS
8.4.4 PRODUCT PORTFOLIO
8.4.5 BUSINESS PERFORMANCE
8.4.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.5. DANAHER CORPORATION
8.5.1 COMPANY OVERVIEW
8.5.2 COMPANY SNAPSHOT
8.5.3 OPERATING BUSINESS SEGMENTS
8.5.4 PRODUCT PORTFOLIO
8.5.5 BUSINESS PERFORMANCE
8.5.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.6. FOUNDATION MEDICINE, INC.
8.6.1 COMPANY OVERVIEW
8.6.2 COMPANY SNAPSHOT
8.6.3 OPERATING BUSINESS SEGMENTS
8.6.4 PRODUCT PORTFOLIO
8.6.5 BUSINESS PERFORMANCE
8.6.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.7. MYRIAD GENETICS, INC.
8.7.1 COMPANY OVERVIEW
8.7.2 COMPANY SNAPSHOT
8.7.3 OPERATING BUSINESS SEGMENTS
8.7.4 PRODUCT PORTFOLIO
8.7.5 BUSINESS PERFORMANCE
8.7.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.8. ROCHE
8.8.1 COMPANY OVERVIEW
8.8.2 COMPANY SNAPSHOT
8.8.3 OPERATING BUSINESS SEGMENTS
8.8.4 PRODUCT PORTFOLIO
8.8.5 BUSINESS PERFORMANCE
8.8.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.9. THERMO FISHER SCIENTIFIC
8.9.1 COMPANY OVERVIEW
8.9.2 COMPANY SNAPSHOT
8.9.3 OPERATING BUSINESS SEGMENTS
8.9.4 PRODUCT PORTFOLIO
8.9.5 BUSINESS PERFORMANCE
8.9.6 KEY STRATEGIC MOVES AND DEVELOPMENT
8.10. QIAGEN N.V.
8.10.1 COMPANY OVERVIEW
8.10.2 COMPANY SNAPSHOT
8.10.3 OPERATING BUSINESS SEGMENTS
8.10.4 PRODUCT PORTFOLIO
8.10.5 BUSINESS PERFORMANCE
8.10.6 KEY STRATEGIC MOVES AND DEVELOPMENT
LIST OF TABLES
TABLE 1. GLOBAL COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 2. IMMUNOHISTOCHEMISTRY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 3. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 4. EUROPE IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 5. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 6. REST OF WORLD IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 7. POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 8. NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 9. EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 10. ASIA-PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 11. REST OF WORLD POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 12. NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 13. NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 14. EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 15. ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 16. REST OF WORLD NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 17. IN SITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 18. NORTH AMERICA IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 19. EUROPE IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 20. ASIA-PACIFIC IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 21. REST OF WORLD IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 22. OTHER TECHNOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 23. NORTH AMERICA OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 24. EUROPE OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 25. ASIA-PACIFIC OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 26. REST OF WORLD OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 28. GLOBAL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 29. LUNG CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 30. NORTH AMERICA LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 31. EUROPE LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 32. ASIA-PACIFIC LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 33. REST OF WORLD LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 34. COLORECTAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 35. NORTH AMERICA COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 36. EUROPE COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 37. ASIA-PACIFIC COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 38. REST OF WORLD COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 39. BREAST CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 40. NORTH AMERICA BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 41. EUROPE BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 42. ASIA-PACIFIC BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 43. REST OF WORLD BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 44. BLOOD CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 45. NORTH AMERICA BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 46. EUROPE BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 47. ASIA-PACIFIC BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 48. REST OF WORLD BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 49. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 50. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 51. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 52. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 53. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 54. ONCOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 55. NORTH AMERICA ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 56. EUROPE ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 57. ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 58. REST OF WORLD ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 59. NEUROLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 60. NORTH AMERICA NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 61. EUROPE NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 62. ASIA-PACIFIC NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 63. REST OF WORLD NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 64. OTHER INDICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 65. NORTH AMERICA OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 66. EUROPE OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 67. ASIA-PACIFIC OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 68. REST OF WORLD OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 69. GLOBAL COMPANION DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 70. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 71. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 72. NORTH AMERICA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 73. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 74. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 75. U.S. ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 76. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 77. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 78. CANADA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 79. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 80. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 81. MEXICO ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 82. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 83. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 84. EUROPE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 85. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 86. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 87. GERMANY ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 88. UK COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 89. UK COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 90. UK ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 91. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 92. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 93. FRANCE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 94. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 95. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 96. REST OF EUROPE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 99. ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 100. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 101. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 102. AUSTRALIA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 103. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 104. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 105. JAPAN ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 106. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 107. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 108. CHINA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 109. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 110. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 111. REST OF ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 112. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 113. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 114. REST OF WORLD ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 115. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 116. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 117. BRAZIL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 118. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 119. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 120. SOUTH AFRICA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 121. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
TABLE 122. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 123. REMAINING COUNTRIES ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
TABLE 124. ABBOTT LABORATORIES MOLECULAR, INC.: COMPANY SNAPSHOT
TABLE 125. ABBOTT LABORATORIES MOLECULAR, INC.: OPERATING SEGMENTS
TABLE 126. ABBOTT LABORATORIES MOLECULAR, INC.: PRODUCT PORTFOLIO
TABLE 127. ABBOTT LABORATORIES MOLECULAR, INC.: KEY STRATERGY
TABLE 128. AGILENT: COMPANY SNAPSHOT
TABLE 129. AGILENT: OPERATING SEGMENTS
TABLE 130. AGILENT: PRODUCT PORTFOLIO
TABLE 131. AGILENT: KEY STRATERGY
TABLE 132. ARUP LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 133. ARUP LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 134. ARUP LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 135. ARUP LABORATORIES, INC.: KEY STRATERGY
TABLE 136. BIOMERIEUX: COMPANY SNAPSHOT
TABLE 137. BIOMERIEUX: OPERATING SEGMENTS
TABLE 138. BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 139. BIOMERIEUX: KEY STRATERGY
TABLE 140. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 141. DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 142. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 143. DANAHER CORPORATION: KEY STRATERGY
TABLE 144. FOUNDATION MEDICINE, INC.: COMPANY SNAPSHOT
TABLE 145. FOUNDATION MEDICINE, INC.: OPERATING SEGMENTS
TABLE 146. FOUNDATION MEDICINE, INC.: PRODUCT PORTFOLIO
TABLE 147. FOUNDATION MEDICINE, INC.: KEY STRATERGY
TABLE 148. MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
TABLE 149. MYRIAD GENETICS, INC.: OPERATING SEGMENTS
TABLE 150. MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO
TABLE 151. MYRIAD GENETICS, INC.: KEY STRATERGY
TABLE 152. ROCHE: COMPANY SNAPSHOT
TABLE 153. ROCHE: OPERATING SEGMENTS
TABLE 154. ROCHE: PRODUCT PORTFOLIO
TABLE 155. ROCHE: KEY STRATERGY
TABLE 156. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 157. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 158. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 159. THERMO FISHER SCIENTIFIC: KEY STRATERGY
TABLE 160. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 161. QIAGEN N.V.: OPERATING SEGMENTS
TABLE 162. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 163. QIAGEN N.V.: KEY STRATERGY
LIST OF FIGURES
FIGURE 1. GLOBAL COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 2. IMMUNOHISTOCHEMISTRY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 3. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 4. EUROPE IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 5. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 6. REST OF WORLD IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 7. POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 8. NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 9. EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 10. ASIA-PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 11. REST OF WORLD POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 12. NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 13. NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 14. EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 15. ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 16. REST OF WORLD NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 17. IN SITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 18. NORTH AMERICA IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 19. EUROPE IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 20. ASIA-PACIFIC IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 21. REST OF WORLD IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 22. OTHER TECHNOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 23. NORTH AMERICA OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 24. EUROPE OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 25. ASIA-PACIFIC OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 26. REST OF WORLD OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 27. GLOBAL COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 28. GLOBAL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 29. LUNG CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 30. NORTH AMERICA LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 31. EUROPE LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 32. ASIA-PACIFIC LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 33. REST OF WORLD LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 34. COLORECTAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 35. NORTH AMERICA COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 36. EUROPE COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 37. ASIA-PACIFIC COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 38. REST OF WORLD COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 39. BREAST CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 40. NORTH AMERICA BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 41. EUROPE BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 42. ASIA-PACIFIC BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 43. REST OF WORLD BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 44. BLOOD CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 45. NORTH AMERICA BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 46. EUROPE BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 47. ASIA-PACIFIC BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 48. REST OF WORLD BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 49. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 50. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 51. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 52. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 53. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 54. ONCOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 55. NORTH AMERICA ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 56. EUROPE ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 57. ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 58. REST OF WORLD ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 59. NEUROLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 60. NORTH AMERICA NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 61. EUROPE NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 62. ASIA-PACIFIC NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 63. REST OF WORLD NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 64. OTHER INDICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 65. NORTH AMERICA OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 66. EUROPE OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 67. ASIA-PACIFIC OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 68. REST OF WORLD OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 69. GLOBAL COMPANION DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 70. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 71. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 72. NORTH AMERICA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 73. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 74. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 75. U.S. ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 76. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 77. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 78. CANADA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 79. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 80. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 81. MEXICO ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 82. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 83. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 84. EUROPE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 85. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 86. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 87. GERMANY ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 88. UK COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 89. UK COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 90. UK ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 91. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 92. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 93. FRANCE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 94. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 95. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 96. REST OF EUROPE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 99. ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 100. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 101. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 102. AUSTRALIA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 103. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 104. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 105. JAPAN ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 106. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 107. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 108. CHINA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 109. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 110. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 111. REST OF ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 112. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 113. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 114. REST OF WORLD ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 115. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 116. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 117. BRAZIL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 118. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 119. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 120. SOUTH AFRICA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 121. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD
FIGURE 122. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 123. REMAINING COUNTRIES ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD
FIGURE 124. ABBOTT LABORATORIES MOLECULAR, INC.: NET SALES,2017-2019
FIGURE 125. AGILENT: NET SALES,2017-2019
FIGURE 126. ARUP LABORATORIES, INC.: NET SALES,2017-2019
FIGURE 127. BIOMERIEUX: NET SALES,2017-2019
FIGURE 128. DANAHER CORPORATION: NET SALES,2017-2019
FIGURE 129. FOUNDATION MEDICINE, INC.: NET SALES,2017-2019
FIGURE 130. MYRIAD GENETICS, INC.: NET SALES,2017-2019
FIGURE 131. ROCHE: NET SALES,2017-2019
FIGURE 132. THERMO FISHER SCIENTIFIC: NET SALES,2017-2019
FIGURE 133. QIAGEN N.V.: NET SALES,2017-2019